Sindrom Hepatorenal

01Pathophysiology

The central mechanism of hepatorenal syndrome is a profound imbalance between splanchnic vasodilation and renal vasoconstriction. In advanced cirrhosis, portal hypertension causes excessive release of vasodilators, primarily nitric oxide, into the splanchnic circulation. This leads to arterial underfilling in the systemic circulation despite a normal or even elevated total blood volume. The body perceives this as hypovolemia and activates compensatory systems: the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and antidiuretic hormone (ADH, vasopressin) secretion.

These neurohormonal responses cause intense renal afferent arteriolar vasoconstriction, which dramatically reduces renal perfusion and glomerular filtration rate (GFR). The kidneys themselves are structurally intact, which is why this is classified as a functional renal failure. If you were to transplant these kidneys into a patient without liver disease, they would work normally. This distinguishes hepatorenal syndrome from intrinsic renal diseases like acute tubular necrosis (ATN).

The reason the patient has low urine sodium ( mEq/L) is that the kidneys are avidly reabsorbing sodium and water in response to the perceived hypovolemia. The urine sediment remains bland (no muddy brown granular casts, no red cell casts, no heavy proteinuria) because there is no direct structural tubular or glomerular injury.

A common precipitant is SBP, which worsens the vasodilatory state through cytokine release, further depleting effective arterial blood volume. Large-volume paracentesis without adequate albumin replacement causes a similar hemodynamic collapse. The key teaching point is that hepatorenal syndrome is ultimately a disease of circulatory dysfunction in the setting of liver failure, not a primary kidney disease.

02Classification and Clinical Manifestation

The revised International Club of Ascites (ICA) criteria have updated the classification from the older Type 1 / Type 2 framework:

The distinction matters on exam vignettes because the acute form (HRS-AKI) is the one most commonly tested and the one that demands urgent intervention. The chronic form (HRS-NAKI) typically presents as the patient whose ascites simply cannot be controlled with diuretics, and the renal impairment is discovered during routine labs.

03Diagnostic Workup

Hepatorenal syndrome is a diagnosis of exclusion. There is no single confirmatory test that proves it. The workup is designed to systematically rule out every other cause of renal failure in a cirrhotic patient.

The first step when a cirrhotic patient develops a rising creatinine is to stop all diuretics and nephrotoxic medications. This alone can reverse prerenal azotemia caused by over-diuresis or drug-induced injury.

If the creatinine does not improve, the next step is the albumin volume expansion challenge: 1 g/kg per day (capped at 100 g/day) for at least 48 hours with concurrent diuretic withdrawal. If renal function improves with this maneuver, the diagnosis is simple prerenal azotemia, not hepatorenal syndrome. Failure to respond to albumin is one of the defining criteria.

Simultaneously, you must obtain a urinalysis with sediment examination. The hallmark of hepatorenal syndrome is a bland sediment. If you see muddy brown granular casts, the diagnosis shifts to ATN. If you see RBC casts or heavy proteinuria ($>500>\; 500$ mg/day), consider glomerulonephritis.

A renal ultrasound should be performed to exclude obstructive uropathy. A diagnostic paracentesis is essential to rule out SBP, which is both a common precipitant and a treatable condition that, when addressed, may reverse the renal impairment.

The key exam concept: there is no gold standard imaging or biopsy that confirms hepatorenal syndrome. The diagnosis is made clinically by meeting all of the following: (1) cirrhosis with ascites, (2) rising creatinine meeting criteria, (3) no improvement after diuretic withdrawal and albumin expansion, (4) absence of shock, (5) no current or recent nephrotoxic drug use, and (6) no structural kidney disease on urine analysis.

04Management and Treatment

Acute Stabilization (HRS-AKI): The immediate priority is to stop all offending agents (diuretics, nephrotoxins) and begin the albumin challenge. If no improvement occurs within 48 hours and the diagnosis of hepatorenal syndrome is established, start a vasoconstrictor. Terlipressin is the best-studied agent and is the preferred choice when available. The rationale for vasoconstrictor therapy is to counteract splanchnic vasodilation, thereby improving effective circulating volume and restoring renal perfusion. Albumin works synergistically by expanding intravascular volume.

A treatment course with terlipressin and albumin typically runs for up to 14 days. If creatinine drops to below 1.5 mg/dL, this is considered a complete response. Partial response (creatinine drop $\ge 50\backslash geq\; 50\%$ but still above 1.5 mg/dL) still confers a survival benefit.

If terlipressin is unavailable, the midodrine plus octreotide regimen is the most commonly tested alternative. Midodrine is an alpha-1 agonist that raises systemic vascular resistance, while octreotide inhibits splanchnic vasodilator release. This combination is less effective than terlipressin but is widely accessible.

In the ICU, norepinephrine is the vasoconstrictor of choice, given as a continuous drip. It has shown comparable efficacy to terlipressin in clinical trials.

Long-term Management: Regardless of the short-term vasoconstrictor response, all patients with hepatorenal syndrome should be listed for liver transplantation as soon as feasible. Hepatorenal syndrome carries a very high recurrence rate once vasoconstrictor therapy is stopped. After successful liver transplantation, renal function typically recovers because the underlying hemodynamic derangement resolves.

An important contraindication to note: terlipressin is contraindicated in patients with ischemic cardiovascular disease due to its potent vasoconstrictive effects, which can precipitate coronary or mesenteric ischemia.

SBP prophylaxis with albumin: For patients admitted with SBP, albumin at 1.5 g/kg on day 1 and 1 g/kg on day 3 significantly reduces the incidence of hepatorenal syndrome and mortality. This is a frequently tested prevention strategy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on hepatorenal syndrome questions is by failing to recognize it as a diagnosis of exclusion and jumping to the diagnosis before completing the required workup. The exam will often present a cirrhotic patient with a rising creatinine and tempt you to choose "start terlipressin" immediately. But the correct next step is almost always to stop diuretics, check a urinalysis, and give an albumin challenge first. You cannot diagnose hepatorenal syndrome until you have shown that the creatinine does not respond to volume expansion.

A second common trap involves confusing hepatorenal syndrome with ATN. Both occur in critically ill cirrhotic patients. The discriminator the exam is testing is the urine sediment: bland and clean in hepatorenal syndrome, muddy brown granular casts in ATN. If a vignette mentions casts, hepatorenal syndrome is wrong.

Another tested concept: the vignette describes a patient with SBP and asks for the best step to prevent hepatorenal syndrome. The answer is albumin infusion at the time of SBP diagnosis (1.5 g/kg day 1, 1 g/kg day 3), not a vasoconstrictor.

Finally, remember that hepatorenal syndrome is reversible with liver transplantation. If a question asks about the definitive treatment, the answer is never "lifelong dialysis." Dialysis is only a bridge, and without transplantation, it does not change the outcome. The core competency being tested is your ability to recognize functional renal failure in the context of liver disease, correctly sequence the diagnostic evaluation, and understand that the kidneys are victims of the hemodynamic catastrophe caused by the failing liver.